menu
    • menu
    [{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Proton Boron Capture-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TAE Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"HDX Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"BNCT","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TAE Life Sciences \/ HDX Corporation","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life Sciences \/ HDX Corporation"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Biddle Sawyer Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"TC220","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TAE Life Sciences \/ TAE Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"TAE Life Sciences \/ TAE Life Sciences"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"P-Borono-L-Phenylalanine","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TAE Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life Sciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by TAE Life Sciences

    Menu

    TAE Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TAE Life Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            TAE Life Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P-Borono-L-Phenylalanine

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TAE Life Sciences' Research on Boronotyrosine (BTS) Drug Shows Promise in Advancing Cancer-Fighting Potential ...

                            Details : BPA (boronophenylalanine) is an engineered targeting boron pharmaceuticals to deliver the cellular precision and curative power of BNCT. It is being evaluated for the treatment of head and neck, brain, breast, melanoma and other cancers.

                            Brand Name : BAP

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 21, 2023

                            Lead Product(s) : P-Borono-L-Phenylalanine

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TAE Life Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            TAE Life Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TC-220

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Biddle Sawyer Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            TAE Life Sciences Signs Biddle Sawyer to Manufacture Boronated TC220 Drug for BNCT Cancer Treatment

                            Details : Under the agreement, Biddle will serve as the exclusive supplier of TC220, a proprietary boronated amino acid analog developed by TAE Life Sciences to support BNCT cancer treatment.

                            Brand Name : TC220

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 15, 2023

                            Lead Product(s) : TC-220

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Biddle Sawyer Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TAE Life Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            TAE Life Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNCT

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : HDX Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            TAE Life Sciences Announces Partnership with HDX Corporation for Launch of Boron Neutron Capture Therapy in So...

                            Details : TLS will provide support and training to HDX and intends to work with HDX to develop a local-language training and clinical education base in the future. BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containi...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 10, 2022

                            Lead Product(s) : BNCT

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : HDX Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TAE Life Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            TAE Life Sciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Proton Boron Capture-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness

                            Details : Results indicate that boron-11 concentrations of 80.4 ppm from sodium borocaptate (BSH) or 86.9 ppm from 4-borono-L-phenylalanine (BPA) treatments did not affect the biological effectiveness of proton beams due to proton–boron reactions in the DU145 pr...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 22, 2022

                            Lead Product(s) : Proton Boron Capture-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth